Incidence and prevalence of polymyxin resistant bacterial strains in the clinical and environmental samples in India: a systematic review and meta-analysis

Sambit K. Dwibedy[1,2], **Indira Padhy**[1], **Aditya K. Panda**[1], **Saswat S. Mohapatra**[1]*

[1]Department of Biotechnology, Berhampur University, Bhanja Bihar, Berhampur- 760007, Odisha, India

[2]Department of Zoology, SBRG Women's College, Berhampur- 760001, Odisha, India

For Correspondence- saswatsmohapatra@gmail.com

Abstract

Introduction: Polymyxins, the cationic lipopeptide antibiotics, are considered to be the last

line of therapeutics against the multi-drug resistant (MDR) pathogenic Gram-negative

bacteria. Unfortunately, the rising cases of polymyxin-resistant strains from across the globe

have adversely impacted the available treatment options. While the molecular mechanisms

responsible for developing polymyxin resistance (Pol^R) are understood to a great extent, the

prevalence of Pol^R strains in India is not investigated systematically.

Method: For this study, a systematic search for relevant articles was performed in the

relevant databases for the period January 2015 to August 2023. A meta-analysis was

performed using the comprehensive meta-analysis software (V.3) to determine the overall

prevalence of Pol^R bacterial strains in India. Publication biases were assessed using funnel

plots and Egger's regression analysis.

Result: Considering a total of 79 studies selected based on the relevant inclusion and

exclusion criteria, the present meta-analysis found the rate of Pol^R bacteria in India to be at

12.7%, which is higher than the global average. Among the Indian States, Tamil Nadu topped

with the highest prevalence of Pol^R at 23%. Investigating the contribution of the mobile

colistin resistance (*mcr*) genes, it was observed that among the Pol^R strains, 8.6 % were *mcr*

positive.

Conclusion: The *mcr*-positive strains reported from India could be an underestimation of the

actual numbers due to the non-inclusion of *mcr* screening in many previous studies. Our

study provides insight into the state of the Pol^R situation in India, which may be useful to

develop a monitoring strategy to contain the spread of such strains and preserve the potency

of the polymyxins.

Keywords: Polymyxin resistance, colistin resistance, *mcr*, India, meta-analysis

INTRODUCTION

The significant use of antibiotics in healthcare, and agriculture, and their indiscriminate prophylactic consumption has driven the rise of antibiotic-resistant bacterial pathogens. Infections caused by antibiotic-resistant bacteria are increasingly becoming fatal due to the non-availability of potent antibiotics against them. As per an estimate, drug-resistant pathogens caused 4.95 million deaths in 2019 [1], predicted to rise to 10 million deaths annually by 2050 [2]. Considering the significant economic consequences of rising drug-resistant infections, urgent mitigation measures are warranted.

Antibiotic-resistant bacteria belonging to the Gram-negative type pose a significant challenge to treatment as increasing reports of resistance to third and fourth generations of cephalosporins are reported globally [3]. In this unprecedented situation, polymyxins, a group of cationic peptide antibiotic, remains the last option for treatment [4,5]. Polymyxin was initially isolated in 1947 from a soil bacterium *Paenibacillus polymyxa* [6], and approved for clinical use in 1959 against Gram-negative bacteria. Due to their nephrotoxic and neurotoxic properties, polymyxins were prohibited for clinical use in the 1970s [7,8], and were consequently substituted by aminoglycosides, quinolones, and β-lactams. However, with the rising infections caused by multi-drug resistant (MDR) Gram-negative bacteria (GNB) such as *Klebsiella pneumoniae*, *Acinetobacter baumannii*, and *Pseudomonas aeruginosa*, and failure of the frontline antibiotics, polymyxins have re-emerged albeit with some modifications in the chemical structure as the last-resort antibiotic option against GNB [4,9].

Polymyxins are of five types (polymyxin A to polymyxin E), of which colistin (polymyxin E) and polymyxin B are approved for clinical use [10]. Structurally, polymyxins are cationic decapeptide consisting of a central cyclic heptapeptide with a tripeptide side-chain acylated at the N-terminus by a fatty acid tail [11,12]. The primary target of cationic polymyxin is the negatively charged outer membrane (OM) of GNB. Polymyxin destabilizes the OM lipopolysaccharide (LPS) by displacing the divalent cations Mg^{2+} and Ca^{2+} resulting in enhanced permeability of the membrane and leading to leakage of cytoplasmic content that ultimately causes cell death [5,13,14].

The extensive use of polymyxins in the preceding decade in both healthcare and animal feeds has triggered the emergence of polymyxin-resistant (Pol^R) bacterial strains across the globe. Pol^R bacterial species such as *K. pneumoniae* [15–17], *P. aeruginosa* [4,18], *A. baumannii* [19], *E. coli* [20], *Shigella sonnei* [21], *Salmonella enterica* [22], *Enterobacter aerogenes* and *Enterobacter*

cloacae [23] have been reported from different parts of the world that have adversely affected

the healthcare sectors. Moreover, the detection of Pol^R GNB in both clinical and

environmental samples has made the situation alarming.

The primary mechanism responsible for Pol^R development is the remodelling of the OM in

GNB making it increasingly positive [by the addition of 4-amino-4-deoxy L-arabinose (L-

Ara4N) or phosphoethanolamine (pEtN)], leading to the repulsion of cationic polymyxins [4,13].

The OM remodelling is generally carried out by bacterial two-component signal transduction

systems (TCS). TCS generally sense the environmental cues and signal appropriately to

modulate the expression of genes involved in the response mechanisms. PhoPQ and PmrAB

are the two primary TCSs in the GNB involved in the OM remodelling in response to various

stresses including polymyxin treatment [5,13]. Apart from PhoPQ and PmrAB TCSs, there are

several other such systems reported in various bacterial species [14,24,25]. Though organisms can

develop resistance to polymyxins via TCS, there are many GNB like *Serratia marcescens*,

Proteus mirabilis, *Proteus penneri*, *Proteus vulgaris*, *Providencia rettgeri*, *Providencia*

stuartii, *Vibrio cholerae*, *Campylobacter spp.*, *Legionella spp.*, *Morganella morganii*,

Burkholderia spp., *Edwardsiella spp.*, *Aeromonas jandaei*, *Aeromonas hydrophila*,

Acinetobacter junii, *Neisseria spp.* that are naturally resistant to polymyxins due to the

constitutive expression of the *arnBCADTEF* operon and/or the *eptB* gene, which increase the

charge of LPS by addition of pEtN and/or L-Ara4N [4,26]. Moreover, all Gram-positive and

anaerobic bacteria are also inherently resistant to polymyxins.

Though chromosome-encoded polymyxin resistance is the prevalent mechanism, the

detection of the plasmid-borne mobile colistin resistance (*mcr*) gene from the bacteria *E. coli*

and *K. pneumoniae* in China has made the situation alarming [20]. The *mcr* gene encodes a

pEtN transferase enzyme that catalyses the addition of a pEtN residue to lipid-A moiety

which alters the net charge of the LPS reducing the binding of polymyxin. To date, ninety-

eight *mcr* alleles have been discovered belonging to ten different classes of *mcr* genes (*mcr1-*

mcr10) among many GNB pathogens. Bacterial plasmids bearing the *mcr* genes have been

reported from across the globe. Moreover, the different *mcr* classes have shown distinct

geographical distribution [27,28]. As the potential of rapid dissemination of plasmid-borne *mcr*

genes is significantly high, it is pertinent to conduct periodic surveillance to monitor their

distribution in the environment and clinic.

In the Indian context, *mcr* genes have been reported in several studies conducted using

clinical samples [29], hospital sewage [30], urban sewage water [31], and food samples [32]. However,

a comprehensive analysis of the distribution of *mcr* genes across India is lacking. It is
important to highlight that the increasing number of carbapenem-resistant pathogenic bacteria
has made India one of the top users of polymyxins in the clinic. Furthermore, the use of
colistin as a growth promoter in poultry farms has triggered the spread of Pol^R GNB in the
environment. Though the Govt. of India has banned the use of colistin in farm animals since
2019, the impact of their extensive use before 2019 is yet to be assessed. Very few
investigations have been carried out in the Indian context, especially using environmental
samples to understand the dynamics of Pol^R bacterial strains in the environment and the
incidence of *mcr*-positive bacterial strains from across India.

The current meta-analysis was performed to determine the pattern and spread of Pol^R
bacterial strains in India and to find a correlation between Pol^R and the presence of the *mcr*
genes.

MATERIALS & METHODS

Using published articles, the present study was conducted to determine the prevalence and
spread of Pol^R Gram-negative bacteria (GNB) from clinical and environmental sources in
India and the contribution of *mcr* genes in gaining the resistance phenotype. The study was
undertaken as per the guidelines of Systematic Reviews and Meta-analyses (PRISMA) [33].

Data collection

Databases like PubMed, Google Scholar, Science Direct, and Scopus were extensively
searched using the keywords "polymyxin resistance", "colistin resistance", "mobile colistin
resistance gene" and "India". Original research articles with reports of Pol^R bacteria from
India, published between January 2015 to August 2023 were included in this study. The last
search was performed on 31st August 2023.

Inclusion criteria

For the meta-analysis, we only included articles that met the following requirements: 1) the
samples used in the report must hail from the Indian population, 2) data on resistance to
polymyxin B and/or colistin must be available, 3) the article must mention the total sample
size and the number of Pol^R strains isolated or the prevalence frequency, and 4) the article
must be published in English.

Exclusion criteria

The following exclusion criteria were strictly followed: 1) studies with no Pol^R isolate were excluded from this analysis; 2) studies conducted outside India were not considered; 3) studies that were not published in English, were not peer-reviewed, and were published before 2015 were excluded.

Data Extraction

Data were extracted from relevant articles that were qualified based on the study's inclusion and exclusion criteria. Each report was individually screened and investigated for eligibility by two different authors (SKD and IP). Following a thorough review, the following information was extracted and summarised for each study: first author name, publication year, State, or UT (Union Territories) of occurrence, total sample size, the total number of Pol^R isolates, reported Pol^R bacteria, resistance detection method, genes involved in resistance development, and *mcr* gene screening status. For further analysis, the data were tabulated in a Microsoft Excel sheet.

Subgrouping of data

The research articles with Pol^R reports were classified into two groups based on criteria such as sample size (more than one) and the involvement of *mcr* genes in the development of Pol^R. Studies reporting a specific number of samples containing both Pol^R and susceptible isolates and a particular number of Pol^R bacteria as event were placed in the first group. This group was further subdivided based on the States or UTs from where they were reported. In this classification system, those States were included that have at least four different reports on Pol^R isolates. In the second group, those reports were included where *mcr* gene screening status was mentioned clearly in the study.

Quality assessment

The quality of all eligible reports was determined by the Newcastle–Ottawa Scale (NOS) and only the high-quality reports were considered for the present meta-analysis. According to the NOS guidelines, qualitative scores are given as stars, and a total score of five stars or more for a study is considered a high-quality report.

Meta-analysis

To measure relative risk, we included articles reporting the prevalence of Pol^R bacteria and the contribution of *mcr* genes in this meta-analysis. All statistical analyses were performed using Comprehensive Meta-Analysis (CMA) software (version 3.0; Biostat Inc. USA). The

generated data were visualized using forest plots. Publication bias in the included studies was

assessed using funnel plots with visual analysis [34] and Egger regression analysis [35]. The

heterogeneity of the studies was examined using the Cochrane Q statistics [36] and I^2 statistics

[37]. Based on the outcome of the heterogeneity analysis, a fixed-effect model (homogenous) or

random-effect model (heterogeneous) was used for the meta-analysis.

Overall, 79 articles reporting the prevalence of Pol^R isolates in India were subjected to meta-

analysis, whereas 56 reports were included to decipher the role of *mcr* gene in the polymyxin

resistance phenotype. Of the 56 reports of *mcr* contribution to Pol^R, 41 were eligible for the

meta-analysis. The combined event rate and 95% confidence interval were calculated to

determine the frequency of Pol^R isolates in India and the contribution of *mcr* to polymyxin

resistance. In addition, sensitivity analysis was performed to explore the robustness of the

meta-analysis by excluding one study at a time, performing the meta-analysis, and comparing

it with the results of the parent analysis.

RESULT

Literature review and screened results

Overall, 1346 articles were obtained by searching different databases with suitable keywords

(PubMed = 760, Google Scholar = 411, Science Direct = 109, Scopus = 66). The article

selection approach is presented in a PRISMA flow chart (Fig. 1). A total of 79 eligible

articles reporting Pol^R and 41 articles reporting the contribution of *mcr* were included in the

meta-analysis after careful screening according to the stipulated inclusion and exclusion

criteria.

Publication bias

Visual analysis of the funnel plot and Egger's regression analysis showed the absence of

publication bias in the analysis of the incidence of Pol^R bacteria in India (intercept: 0.21, 95%

CI = -2.04 to 2.45, p = 0.85), as well as in the analysis of the role of *the mcr* gene in Pol^R

(intercept: -1.3, 95% CI = -2.69 to 0.08, p = 0.065) (Table 1).

Furthermore, after the categorization of all studies according to the states from which they

were reported, the funnel plot and Egger's regression analysis revealed significant biases

while analysing the incidence of Pol^R bacteria in Tamil Nadu (intercept: 7.18, 95% CI = 0.82

to 15.53, p = 0.03) and Uttar Pradesh (intercept: 5.98, 95% CI = 0.71 to 11.25, p = 0.03).

However, data on the incidence of Pol^R bacteria in states such as Odisha, Delhi, Maharashtra,

and West Bengal have demonstrated an absence of publication bias. The trim-and-fill method
was employed to adjust for publication bias.

Heterogeneity analysis

215 Cochrane Q and I^2 measurements demonstrated significant heterogeneity among the included
216 studies. Hence, a random-effects model was used for all meta-analyses (Table 1).

Prevalence of Pol^R bacteria in India

After investigating 79 reports, the present meta-analysis found that the rate of Pol^R bacteria in
India was 12.7% (Fig. 2). Out of 28 states and eight UTs in India, 19 states and two UTs have
reported the presence of Pol^R bacterial strains. Among all the states that have reported Pol^R,
Tamil Nadu, Odisha, and Uttar Pradesh are the top three, where the rate of Pol^R is higher than
the Indian average by 23.5%, 16.5%, and 14%, respectively. Upon State-wise analysis, Tamil
Nadu, Odisha, Uttar Pradesh, Delhi, West Bengal, and Maharashtra showed Pol^R values of
23.5%, 16.5%, 14%, 12%, 8.1%, and 2.2%, respectively (Fig. 3).

Role of *mcr* gene in the development of Pol^R

226 Furthermore, to understand the prevalence of *mcr* genes in Pol^R bacterial isolates in
227 comparison with other possible mechanisms in India, 41 reports with positive *mcr* gene
228 screening status and a sample size of more than one (Pol^R isolate) criterion were considered
229 for the analysis. The results are shown in Fig. 4. The meta-analysis results showed that the
230 contribution of the *mcr* gene to the rise in polymyxin resistance was 8.6% in India.

Sensitivity analysis

Sensitivity analysis was performed to measure the robustness of the meta-analysis by
excluding a single study each time and relating the results to the parental meta-analysis. As
illustrated in Supplementary Fig. 3, no significant deviation was observed in the sensitivity
analysis compared with the original meta-analysis results for studying the incidence of Pol^R
bacteria in India. Furthermore, a meta-analysis on the contribution of the *mcr* gene to Pol^R
also revealed a robust observation, as shown in Supplementary Fig. 4.

DISCUSSION

The current meta-analysis systematically evaluated the incidence of Pol^R bacteria in India,
which was higher than the global average. In this study, we found that 12.7% of GNB were
Pol^R, whereas the global average remained at 10% [38]. A previous study has put the rate of
Pol^R among clinical *Enterobacteriaceae* isolates in India at 13.8% [39].

The present study revealed that GNB resistant to the last line of therapeutics is spread all over

India, and States like Tamil Nadu, Odisha, and Uttar Pradesh have a higher incidence of Pol[R]

strains than the national average. The rising incidence of polymyxin resistance in India could

be attributed to their indiscriminate use in the healthcare sector, in the poultry industry as

growth promoters, and the rapid dissemination of *mcr* genes via horizontal gene transfer.

Even though India has banned the use of colistin in the poultry industry since 2019, its

implications on the spread of Pol[R] may be revealed a few years down the line. Interestingly,

there are no reports of Pol[R] in nine states and six UTs in India, which may be due to the lack

of surveillance in those States and UTs. The overall spread of Pol[R] GNB in India is shown in

Fig. 5A.

Although most of the reports used in this study indicated Pol[R] rates under 20%, few have

reported significantly higher resistance rates [40–45]. These alterations are due to differences in

the procedures adopted for antimicrobial susceptibility testing (AST). In India, AST

methodologies, such as the Kirby-Bauer disk diffusion test, broth microdilution (BMD), agar

dilution, E-test, VITEK-2, gradient diffusion, colistin broth disc elution, rapid polymyxin

Nordmann Poirel Test, Mikrolatest kit, BD Phoenix M50, MicroScan WalkAway 96 Plus,

Micronaut-S and Modified Stokes DDT, have been used. The widely varied detection

methods, where the sensitivity of the individual tests could also vary, might have influenced

the results, making a robust comparison among the studies difficult. Moreover, many

laboratories have primarily performed disk diffusion tests for polymyxin sensitivity.

Polymyxin diffuses poorly in agar plates owing to its high molecular weight, which may

explain the increased Pol[R] detection rate using the disk diffusion method [46].

Meta-analysis revealed that in 8.6% of cases, the *mcr* gene was responsible for spreading the

Pol[R] phenotype in India. In India, after the first detection of the *mcr* gene in a clinical *E. coli*

isolate [47], several reports of *mcr* occurrence have been published [30,32,48–50]. To date, five

classes of *mcr* have been reported in India: *mcr-1*, *mcr-2*, *mcr-3*, *mcr-5*, and *mcr-9*. Of the 82

mcr variants detected, *mcr*-1 was the predominant variant responsible for driving polymyxin

resistance in India. In the current study, the frequency of *mcr*-1 was 89%, whereas the

frequencies of *mcr*-2, *mcr*-3, *mcr*-5, and *mcr*-9 were 1%, 6%, 1%, and 3%, respectively (Fig.

5C). Considering that *mcr*-1 was the first plasmid-borne colistin resistance gene to be

detected, it has spread globally in 6-7 years.

Unlike the distribution of Pol[R] GNB, the spread of *mcr* has been limited to nine states and

two UTs in India (Fig. 5B). Among these states, Uttar Pradesh was found to be the hotspot

for the spread of *mcr* variants, with 48 reports, followed by Tamil Nadu and Assam with 8 and 7 *mcr* variant reports, respectively. However, several reports on Pol^R have not provided sufficient information on *mcr* gene screening status. The limited screening for *mcr* genes among these studies may be responsible for the low rate of detection and reporting of *mcr* genes in India.

As mentioned previously, *mcr* genes are largely plasmid-borne, and various types of plasmids are involved in carrying *mcr* genes in GNB [27,51]. In India, different *mcr* variants were found to be linked with plasmids including IncHI2, InCHI2A, IncX1, IncX4, and FIA Inc [32,41,52]. The association of these plasmids with other antibiotic-resistance genes conferring resistance to carbapenems, cephalosporins, and fosfomycin has also been previously established [53,54]. Although plasmids are the primary genetic vehicle through which *mcr* genes disseminate among bacterial species, their chromosomal integration has also been reported in different bacterial species in India [55–58]. The major advantage of chromosomal integration of *mcr* genes could be their reduced chance of loss from the genome, in the absence of polymyxin selection.

This meta-analysis has certain limitations. Firstly, the current study included articles available in the English language, as a result, publications in other languages have been excluded. Secondly, we searched reports from databases including PubMed, Google Scholar, and Science Direct, so may have missed publications indexed in other databases. Third, as certain Gram-negative bacterial species are inherently resistant to polymyxins, reports on polymyxin resistance from the environmental strains may have been biased toward such species.

CONCLUSION

The present study found that the rate of Pol^R bacterial strains in India was 12.7%, which is higher than the global average. While Pol^R strains have been reported from most of the Indian States and UTs, there are still regions where no data are available, warranting monitoring and surveillance. This study further found that in 8.6% of Pol^R strains, the phenotype was determined by *mcr* genes carried on plasmids. This may be grossly underestimated due to the lack of *mcr* surveillance data in many published articles. As polymyxins are one of the last option antibiotics available against Gram-negative bacterial pathogens, preservation of their antibiotic properties is paramount. However, the increasing incidence of polymyxin resistance in clinics and the environment has the potential to limit antibiotic treatment

options. Therefore, along with developing better versions of polymyxins and/or their derivatives, it is also important to devise strategies to monitor the frequency of Pol^R bacterial species and, thus, the prevalence of *mcr* genes in these species in the Indian environment. Sustained measures need to be in place to contain the further spread of the polymyxin resistance phenotype in the near future.

Author Contributions

Conceptualization: SKD, AKP, and SSM; Data extraction and analysis: SKD, IP, AKP, and SSM; Data validation: SKD and IP; Manuscript writing and reviewing: SKD, AKP, and SSM. All authors agreed to the submitted version.

Funding

This work is supported by the funds received from the Science and Technology Department, Govt. of Odisha (Grant no. ST-BT-MISC-0005-2023-2463/ST, dt. 23-05-2023). Infrastructure support from the "Centre of Excellence on Bioprospecting of Ethno-pharmaceuticals of Southern Odisha (CoE-BESO)" to the Dept. of Biotechnology, Berhampur University is gratefully acknowledged. Indira Padhy is a recipient of the "Biju Patnaik Research Fellowship (BPRF)" from the Science and Technology Department, Govt. of Odisha.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

328   **Figures**

330   **Figure. 1**. The PRISMA flow diagram for the selection, inclusion, and exclusion of studies.

Study name	Statistics for each study				Event rate and 95% CI	Relative weight
	Event rate	Lower limit	Upper limit	Z-Value		
Sharma et al., 2023 A	0.126	0.096	0.165	-12.121		1.38
Hasan et al., 2023	0.010	0.005	0.020	-12.233		1.26
Ranjan et al., 2023	0.090	0.047	0.164	-6.621		1.28
Panda & Pugalia, 2023	0.246	0.178	0.330	-5.330		1.36
Shekhar et al., 2023	0.429	0.277	0.594	-0.842		1.29
Sharma et al., 2023 B	0.402	0.302	0.512	-1.755		1.36
Naz et al., 2023	0.070	0.043	0.111	-9.967		1.34
Shanthini et al., 2023	0.900	0.732	0.967	3.610		1.08
Mallikarjuna & Dhanashree, 2023	0.425	0.322	0.535	-1.337		1.36
Rout et al., 2023	0.129	0.121	0.138	-49.615		1.41
Sharma et al., 2022	0.689	0.541	0.806	2.469		1.30
Elizabeth et al., 2022	0.041	0.024	0.071	-10.672		1.32
Bir et al., 2022	0.227	0.158	0.315	-5.379		1.36
Panigrahi et al., 2022	0.196	0.158	0.241	-10.585		1.39
Naha et al., 2022	0.028	0.015	0.053	-10.467		1.29
Sharma et al, 2022	0.200	0.139	0.279	-6.200		1.36
Singh et al., 2022	0.160	0.061	0.357	-3.040		1.13
Bhatia et al., 2022	0.160	0.061	0.357	-3.040		1.13
Shah et al., 2022	0.063	0.033	0.117	-7.843		1.29
Sahoo et al., 2022	0.129	0.068	0.229	-5.359		1.28
Seethalakshmi et al., 2022	0.032	0.005	0.196	-3.346		0.76
Reddy et al., 2022	0.017	0.012	0.024	-22.488		1.38
Das et al., 2022	0.171	0.120	0.238	-7.473		1.36
Nirwan et al., 2021	0.003	0.002	0.004	-25.110		1.35
Azam et al., 2021	0.033	0.018	0.058	-11.034		1.31
Kar et al., 2021	0.135	0.094	0.190	-8.977		1.37
Rohilla et al., 2021	0.612	0.471	0.737	1.558		1.32
Prasad et al., 2021	0.516	0.445	0.587	0.438		1.39
Sharma et al., 2021 A	0.106	0.058	0.187	-6.362		1.29
Shankar et al., 2021	0.476	0.419	0.533	-0.822		1.40
Sohail et al., 2021	0.179	0.117	0.264	-6.008		1.34
Gunalan et al., 2021	0.147	0.083	0.246	-5.395		1.30
Priyanka et al., 2021	0.596	0.521	0.667	2.508		1.39
Sangale et al., 2021	0.009	0.004	0.019	-12.391		1.26
Khamari et al., 2021	0.050	0.021	0.115	-6.417		1.20
Patnaik et al., 2021	0.150	0.080	0.264	-4.798		1.27
Dhandapani et al., 2021	0.140	0.068	0.266	-4.454		1.24
Bandyopadhyay et al., 2021	0.028	0.007	0.104	-4.958		0.99
Sharma et al., 2021 B	0.025	0.013	0.047	-10.896		1.29
Aarthi et al., 2020	0.025	0.014	0.045	-11.998		1.31
Pathak et al., 2020	0.040	0.029	0.054	-19.694		1.38
Raghupati et al., 2020	0.333	0.190	0.516	-1.790		1.26
Bardhan et al., 2020	0.679	0.572	0.769	3.198		1.35
Khurana et al., 2020	0.215	0.190	0.243	-16.032		1.41
Khamari et al., 2020	0.143	0.036	0.427	-2.346		0.95
Soundari et al., 2020	0.662	0.539	0.766	2.557		1.34
Mitra et al., 2020	0.400	0.285	0.528	-1.539		1.34
Naha et al., 2020	0.005	0.001	0.035	-5.254		0.77
Singh et al., 2020	0.050	0.042	0.059	-33.714		1.41
Das et al., 2020	0.225	0.163	0.302	-6.074		1.37
Sodhi et al., 2020	0.038	0.027	0.053	-17.722		1.38
Waattal et al., 2019	0.324	0.266	0.388	-5.150		1.39
Gogry et al., 2019	0.186	0.143	0.239	-9.141		1.38
Mathur et al., 2019	0.040	0.029	0.056	-18.127		1.38
Sundaramoorthy et al., 2019 A	0.444	0.177	0.749	-0.333		1.03
Sundaramoorthy et al., 2019 B	0.333	0.084	0.732	-0.800		0.87
Sailo et al., 2019 57	0.103	0.034	0.276	-3.542		1.08
Subramaniam & Muthukrishnan, 2019	0.035	0.009	0.130	-4.604		0.99
Amladi et al., 2019	0.093	0.056	0.151	-8.100		1.33
Nandini & Navneeth et al., 2019	0.020	0.008	0.052	-7.705		1.16
Gupta et al., 2019	0.130	0.088	0.186	-8.699		1.36
Garg et al., 2019	0.185	0.130	0.256	-6.958		1.36
Raghupati et al., 2019	0.310	0.222	0.415	-3.446		1.35
Rahman & Ahmad., 2019	0.200	0.133	0.290	-5.545		1.34
Kumar et al., 2018	0.018	0.011	0.029	-16.283		1.35
Singh et al., 2018	0.105	0.069	0.156	-9.290		1.35
Manohar et al., 2017	0.326	0.237	0.430	-3.215		1.36
Ramesh et al., 2016	0.287	0.205	0.386	-3.987		1.36
Pawar et al., 2016	0.100	0.090	0.110	-39.532		1.41
Kumar., 2016	0.968	0.804	0.995	3.346		0.76
Kumar et al., 2016 C	0.077	0.065	0.092	-26.406		1.40
Alagesm et al., 2015	0.030	0.025	0.036	-38.108		1.40
Chakraverti & Tripathi, 2015	0.188	0.149	0.234	-10.387		1.39
Shah et al., 2015	0.030	0.004	0.186	-3.413		0.76
Lunawat et al., 2015	0.219	0.189	0.252	-13.462		1.40
Perween et al., 2015	0.082	0.051	0.130	-9.254		1.34
Figona et al., 2015	0.067	0.028	0.150	-5.701		1.20
Bhatt et al., 2015	0.009	0.005	0.016	-15.572		1.31
Sharma et al., 2015	0.002	0.000	0.017	-6.023		0.77
	0.127	0.101	0.158	-14.868		

Figure. 2. Forest plots demonstrating the event rate of polymyxin-resistant (Pol[R]) bacteria in India. The Comprehensive meta-analysis software v3 (Biostat Inc. USA) was used for the calculation of the event rate and 95% confidence interval and used in the forest plot.

Figure. 3. Forest plots representing the event rate of polymyxin-resistant (Pol^R) bacteria in different states of India (A) Delhi, (B) Maharashtra, (C) Odisha, (D) Tamil Nadu, (E)Uttar Pradesh, and (F) West Bengal.

Study name	Event rate	Lower limit	Upper limit	Z-Value		Relative weight
Talat et al., 2023	0.167	0.023	0.631	-1.469		2.61
Pathak et al., 2023	0.071	0.004	0.577	-1.748		2.04
Shanthini et al., 2023	0.018	0.001	0.230	-2.808		2.09
Rout et al., 2023	0.001	0.000	0.010	-5.196		2.11
Elizabeth et al., 2022	0.417	0.185	0.692	-0.575		3.49
Bir et al., 2022	0.040	0.006	0.235	-3.114		2.74
Naha et al., 2022	0.050	0.003	0.475	-2.029		2.06
Sharma et al., 2022	0.019	0.001	0.244	-2.753		2.09
Reddy et al., 2022	0.065	0.016	0.224	-3.658		3.24
Das et al., 2022	0.018	0.001	0.230	-2.808		2.09
Azam et al., 2021	0.042	0.003	0.425	-2.170		2.07
Nirwan et al., 2021	0.026	0.002	0.310	-2.519		2.09
Singh et al., 2021	0.864	0.652	0.955	2.971		3.43
Elizabeth et al., 2021	0.333	0.084	0.732	-0.800		3.01
Kar et al., 2021	0.018	0.001	0.230	-2.808		2.09
Bandyopadhyay et al., 2021	0.167	0.010	0.806	-1.039		1.93
Sharma et al., 2021	0.050	0.003	0.475	-2.029		2.06
Aarthi et al., 2021	0.042	0.003	0.425	-2.170		2.07
Pathak et al., 2020	0.100	0.038	0.238	-4.169		3.58
Raghupati et al., 2020	0.100	0.014	0.467	-2.084		2.68
Roy et al., 2020	0.875	0.266	0.993	1.287		1.98
Bardhan et al., 2020	0.009	0.001	0.123	-3.341		2.10
Khamari et al., 2020	0.167	0.010	0.806	-1.039		1.93
Soundari et al., 2020	0.047	0.012	0.168	-4.171		3.26
Mitra et al., 2020	0.083	0.021	0.279	-3.247		3.23
Das et al., 2020	0.016	0.001	0.206	-2.907		2.10
Gogry et al., 2019	0.106	0.045	0.231	-4.499		3.66
Shankar et al., 2019	0.008	0.000	0.110	-3.434		2.11
Mathur et al., 2019	0.014	0.001	0.191	-2.973		2.10
Sundaramoorthy et al., 2019 B	0.167	0.010	0.806	-1.039		1.93
Subramaniam & Muthukrishnan, 2019	0.833	0.194	0.990	1.039		1.93
Amladi et al., 2019	0.033	0.002	0.366	-2.341		2.08
Rahman & Ahmad., 2019	0.976	0.713	0.999	2.594		2.09
Ghafur et al., 2019	0.042	0.014	0.123	-5.290		3.48
Kumar et al., 2018	0.028	0.002	0.322	-2.479		2.08
Singh et al., 2018	0.190	0.073	0.412	-2.604		3.54
Aggarwal et al., 2018	0.063	0.004	0.539	-1.854		2.05
Mathur et al., 2018	0.056	0.003	0.505	-1.947		2.06
Manohar et al., 2017	0.017	0.001	0.217	-2.859		2.10
Pragasam et al., 2017	0.056	0.003	0.505	-1.947		2.06
Bernasconi et al., 2016	0.200	0.027	0.691	-1.240		2.57
	0.086	0.050	0.144	-7.941		

Figure. 4. Forest plots demonstrating the contribution of the *mcr* genes in the development of polymyxin resistance in India.

Figure. 5. (A) Distribution of polymyxin-resistant (Pol^R) bacteria across different States and Union Territories (UTs) of India from 79 studies, (B) spread of *mcr* genes across different States and UTs of India, and (C) Pie chart showing the percentage of reported *mcr* variants in India.

347 **Table 1.** Statistics to test the publication bias and heterogeneity.

Study Name (Incidence of Pol^R bacteria)	Egger's Regression Analysis			Heterogeneity Analysis			Model Used
	Intercept	95% Confidence Interval	P Value (2 tailed)	Q value	P-Heterogeneity	I^2 (%)	
India	0.21	-2.04 to 2.45	0.85	3139.76	0.00	97.52	Random
Odisha	2.11	-2.64 to 6.87	0.32	98.03	0.00	92.86	Random
Delhi	-7.84	-18.94 to 3.26	0.14	357.70	0.00	97.76	Random
Maharashtra	-5.85	-17.67 to 5.97	0.17	107.96	0.00	97.22	Random
Tamil Nadu	7.18	0.82 to 15.53	0.03	528.76	0.00	97.92	Random
Uttar Pradesh	5.99	0.71 to 11.25	0.03	285.55	0.00	95.80	Random
West Bengal	-6.99	-23.73 to 9.74	0.27	144.03	0.00	97.22	Random
mcr gene involvement in Pol^R	-1.3	-2.69 to -0.08	0.06	129.71	0.00	69.93	Random

367 **Table 2**. Detailed information on the *mcr* gene reported from India.

mcr gene	Plasmid/ Chromosomal	Bacteria	Source	References
mcr-9.1	IncHI2	*Enterobacter hormaechei*	Broiler faeces	Sreejith et al., 2023 [52]
mcr-5.1	IncX1	*E. coli*	Hospital sewage water	Talat et al., 2022 [30]
mcr-1	FIA Inc	*E. coli*	Clinical isolates	Elizabeth et al., 2022 [59]
mcr-1	Not determined	*Klebsiella pneumoniae*	Clinical isolates	Bir et al., 2022 [60]
mcr-9	Chromosomal	*Enterobacter hormaechei (COL^S)**	Env water sample	Seethalakshmi et al., 2022 [58]
mcr-1 (2)	Plasmid	*E. coli (COL^S)*, E. coli (COL$^{R)}$*	Clinical isolates	Reddy et al., 2022 [61]
mcr-1 (19)	Chromosomal, Plasmid	*Klebsiella pneumoniae (19)*	Clinical isolates	Singh et al., 2021 [62]
mcr-1 (2)	Not determined	*E. coli (2)*	Clinical isolates	Elizabeth et al., 2021 [63]
mcr-1 (4)	Chromosomal	*Pseudomonas aeruginosa*	Clinical isolates	Pathak et al., 2020 [64]
mcr-3.30	Chromosomal	*Aeromonas veronii (COL^S)**	Clinical isolates	Raghupati et al., 2020 [50]
mcr-1 (2)	Not determined	*E. coli*	Clinical isolates	Roy et al., 2020 [65]
mcr-1	Not determined	*K. pneumoniae*	Clinical isolates	Roy et al., 2020 [65]
mcr-1 (2)	IncX4	*E. coli*	Clinical isolates	Soundari et al., 2020 [41]
mcr-1 (2)	Not determined	*Enterobacter cloacae*	Clinical isolates	Mitra et al., 2020 [49]
mcr-2 (3)	Not determined	*Burkholderia cepacia*	Clinical isolates	Mitra et al., 2020 [49]

mcr-2	Not determined	*Pseudomonas aeruginosa*	Clinical isolates	Mitra et al., 2020 [49]
mcr-1	Not determined	Not mentioned	Clinical isolates	Pathak et al., 2020 [57]
mcr-1(5)	Plasmid	*E. coli, A. veronii, A. dhakensis*	Sewage water	Gogry et al., 2019 [31]
mcr-1	Not determined	*E. coli*	Clinical isolates	Subramaniam & Muthukrishnan, 2019 [66]
mcr-1 (20)	Chromosomal	*Acinetobacter baumannii*	Clinical isolates	Rahman & Ahmad., 2019 [56]
mcr-1 (3)	IncX1, InCHI2, InCHI2A	*E. coli*	Poultry and mutton meat	Ghafur et al., 2019 [32]
mcr-1 (4)	Chromosomal	*K. pneumoniae*	Clinical isolates	Singh et al., 2018 [55]
mcr-1	Not determined	*Not mentioned*	River sediment	Marathe et al., 2017 [48]
mcr-1	Plasmid	*E. coli*	Clinical isolates	Kumar et al., 2016 [47]
mcr-1	InCHI2	*E. coli*	Human Stool sample	Bernasconi et al., 2016 [67]

368   Species denoted with * mark indicate insertional inactivation of the *mcr* gene, which leads to polymyxin susceptibility.

REFERENCES

1. Murray CJ, Ikuta KS, Sharara F, *et al.* Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. *The Lancet* 2022: S0140673621027240.

2. O'Neill J. An audience with Jim O'Neill. *Nat Rev Drug Discov* 2016; **15**: 526–526.

3. Darby EM, Trampari E, Siasat P, *et al.* Molecular mechanisms of antibiotic resistance revisited. *Nat Rev Microbiol* 2023; **21**: 280–95.

4. Poirel L, Jayol A, Nordmann P. Polymyxins: Antibacterial Activity, Susceptibility Testing, and Resistance Mechanisms Encoded by Plasmids or Chromosomes. *Clin Microbiol Rev* 2017; **30**: 557–96.

5. Mohapatra SS, Dwibedy SK, Padhy I. Polymyxins, the last-resort antibiotics: Mode of action, resistance emergence, and potential solutions. *J Biosci* 2021; **46**: 85.

6. Benedict RG, Langlykke AF. Antibiotic activity of Bacillus polymyxa. *J Bacteriol* 1947; **54**: 24.

7. Koch-Weser J, Sidel VW, Federman EB, Kanarek P, Finer DC, Eaton AE. Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy. *Ann Intern Med* 1970; **72**: 857–68.

8. Nation RL, Li J. Colistin in the 21st century: *Curr Opin Infect Dis* 2009; **22**: 535–43.

9. Vaara M. Polymyxins and Their Potential Next Generation as Therapeutic Antibiotics. *Front Microbiol* 2019; **10**: 1689.

10. Hamel M, Rolain J-M, Baron SA. The History of Colistin Resistance Mechanisms in Bacteria: Progress and Challenges. *Microorganisms* 2021; **9**: 442.

11. Kwa A, Kasiakou SK, Tam VH, Falagas ME. Polymyxin B: similarities to and differences from colistin (polymyxin E). *Expert Rev Anti Infect Ther* 2007; **5**: 811–21.

12. Nang SC, Azad MAK, Velkov T, Zhou Q (Tony), Li J. Rescuing the Last-Line Polymyxins: Achievements and Challenges Barker E, ed. *Pharmacol Rev* 2021; **73**: 679–728.

13. Olaitan AO, Morand S, Rolain J-M. Mechanisms of polymyxin resistance: acquired and intrinsic resistance in bacteria. *Front Microbiol* 2014; **5**. Available at: http://journal.frontiersin.org/article/10.3389/fmicb.2014.00643/abstract. Accessed December 8, 2021.

14. Yu Z, Qin W, Lin J, Fang S, Qiu J. Antibacterial Mechanisms of Polymyxin and Bacterial Resistance. *BioMed Res Int* 2015; **2015**: 1–11.

15. Antoniadou A, Kontopidou F, Poulakou G, *et al.* Colistin-resistant isolates of Klebsiella pneumoniae emerging in intensive care unit patients: first report of a multiclonal cluster. *J Antimicrob Chemother* 2007; **59**: 786–90.

16. Lim LM, Ly N, Anderson D, *et al.* Resurgence of Colistin: A Review of Resistance, Toxicity, Pharmacodynamics, and Dosing. *Pharmacotherapy* 2010; **30**: 1279–91.

17. Elemam A, Rahimian J, Doymaz M. *In Vitro* Evaluation of Antibiotic Synergy for
Polymyxin B-Resistant Carbapenemase-Producing *Klebsiella pneumoniae. J Clin Microbiol*
2010; **48**: 3558–62.

18. El-Baky RMA, Masoud SM, Mohamed DS, *et al.* Prevalence and Some Possible
Mechanisms of Colistin Resistance Among Multidrug-Resistant and Extensively Drug-
Resistant Pseudomonas aeruginosa. *Infect Drug Resist* 2020; **13**: 323.

19. Hejnar P, Kolář M, Hájek V. CHARACTERISTICS OF ACINETOBACTER STRAINS
(PHENOTYPE CLASSIFICATION, ANTIBIOTIC SUSCEPTIBILITY AND
PRODUCTION OF ß-LACTAMASES) ISOLATED FROM HAEMOCULTURES FROM
PATIENTS AT THE TEACHING HOSPITAL IN OLOMOUC. 1999; **142**.

20. Liu Y-Y, Wang Y, Walsh TR, *et al.* Emergence of plasmid-mediated colistin resistance
mechanism MCR-1 in animals and human beings in China: a microbiological and molecular
biological study. *Lancet Infect Dis* 2016; **16**: 161–8.

21. Ma Q, Huang Y, Wang J, *et al.* Multidrug-resistant Shigella sonnei carrying the plasmid-
mediated mcr -1 gene in China. *Int J Antimicrob Agents* 2018; **52**: 14–21.

22. Borowiak M, Fischer J, Hammerl JA, Hendriksen RS, Szabo I, Malorny B. Identification
of a novel transposon-associated phosphoethanolamine transferase gene, mcr-5, conferring
colistin resistance in d-tartrate fermenting Salmonella enterica subsp. enterica serovar
Paratyphi B. *J Antimicrob Chemother* 2017; **72**: 3317–24.

23. Zeng K, Doi Y, Patil S, Huang X, Tian G-B. Emergence of the Plasmid-Mediated *mcr-1*
Gene in Colistin-Resistant Enterobacter aerogenes and Enterobacter cloacae. *Antimicrob*
Agents Chemother 2016; **60**: 3862–3.

24. Fernández L, Gooderham WJ, Bains M, McPhee JB, Wiegand I, Hancock REW.
Adaptive Resistance to the "Last Hope" Antibiotics Polymyxin B and Colistin in
Pseudomonas aeruginosa Is Mediated by the Novel Two-Component Regulatory System
ParR-ParS. *Antimicrob Agents Chemother* 2010; **54**: 3372–82.

25. Fernández L, Jenssen H, Bains M, Wiegand I, Gooderham WJ, Hancock REW. The Two-
Component System CprRS Senses Cationic Peptides and Triggers Adaptive Resistance in
Pseudomonas aeruginosa Independently of ParRS. *Antimicrob Agents Chemother* 2012; **56**:
6212–22.

26. Yin W, Li H, Shen Y, *et al.* Novel Plasmid-Mediated Colistin Resistance Gene *mcr-3* in
Escherichia coli Bush K, ed. *mBio* 2017; **8**: e00543-17.

27. Nang SC, Li J, Velkov T. The rise and spread of *mcr* plasmid-mediated polymyxin
resistance. *Crit Rev Microbiol* 2019; **45**: 131–61.

28. Gogry FA, Siddiqui MT, Sultan I, Haq QMohdR. Current Update on Intrinsic and
Acquired Colistin Resistance Mechanisms in Bacteria. *Front Med* 2021; **8**: 677720.

29. Singh S, Pathak A, Rahman M, *et al.* Genetic Characterisation of Colistin Resistant
Klebsiella pneumoniae Clinical Isolates From North India. *Front Cell Infect Microbiol* 2021;
11: 666030.

30. Talat A, Usmani A, Khan AU. Detection of *E. coli* IncX1 Plasmid-Mediated *mcr-5.1* Gene in an Indian Hospital Sewage Water Using Shotgun Metagenomic Sequencing: A First Report. *Microb Drug Resist* 2022; **28**: 759–64.

31. Gogry FA, Siddiqui MT, Haq. QMohdR. Emergence of mcr-1 conferred colistin resistance among bacterial isolates from urban sewage water in India. *Environ Sci Pollut Res* 2019; **26**: 33715–7.

32. Ghafur A, Shankar C, GnanaSoundari P, *et al.* Detection of chromosomal and plasmid-mediated mechanisms of colistin resistance in Escherichia coli and Klebsiella pneumoniae from Indian food samples. *J Glob Antimicrob Resist* 2019; **16**: 48–52.

33. Hutton B, Salanti G, Caldwell DM, *et al.* The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations. *Ann Intern Med* 2015; **162**: 777–84.

34. Sterne JA, Egger M. Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. *J Clin Epidemiol* 2001; **54**: 1046–55.

35. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ* 1997; **315**: 629–34.

36. Higgins JPT, Green S eds. *Cochrane Handbook for Systematic Reviews of Interventions*. The Cochrane Collaboration; 2011. Available at: www.handbook.cochrane.org.

37. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ* 2003; **327**: 557.

38. Silva KED, Rossato L, Leite AF, Simionatto S. Overview of polymyxin resistance in Enterobacteriaceae. *Rev Soc Bras Med Trop* 2022; **55**: e0349-2021.

39. Turnidge JD, Bell JM, Jones RN. Emergence of Colistin-Resistant Klebsiella spp., and Enterobacter spp. in the Asia-Pacific (APAC) Region: A SENTRY Antimicrobial Surveillance Program Report (2006). In: Washington DC: American Society for Microbiology, 2007.

40. Bardhan T, Chakraborty M, Bhattacharjee B. Prevalence of Colistin-Resistant, Carbapenem-Hydrolyzing Proteobacteria in Hospital Water Bodies and Out-Falls of West Bengal, India. *Int J Environ Res Public Health* 2020; **17**: 1007.

41. Palani GS, Ghafur A, Krishnan P, Rayvathy B, Thirunarayan M. Intestinal carriage of colistin resistant Enterobacteriaceae in hospitalized patients from an Indian center. *Diagn Microbiol Infect Dis* 2020; **97**: 114998.

42. Priyanka, Meena PR, Meghwanshi KK, Rana A, Singh AP. Leafy greens as a potential source of multidrug-resistant diarrhoeagenic Escherichia coli and Salmonella. *Microbiol Read Engl* 2021; **167**.

43. Rohilla R, Raina D, Singh M, Pandita AK, Patwal S. Evaluation of Sphingomonas paucimobilis as an emerging nosocomial pathogen in a teaching hospital in Uttarakhand. *Iran J Microbiol* 2021; **13**: 617–23.

44. Shanthini T, Manohar P, Hua X, Leptihn S, Nachimuthu R. Detection of Hypervirulent
Klebsiella pneumoniae from Clinical Samples in Tamil Nadu. 2023: 2023.02.19.23286158.
Available at: https://www.medrxiv.org/content/10.1101/2023.02.19.23286158v1. Accessed
September 28, 2023.

45. Shekhar C, Joshi N, Singh A. Prevalence of Multidrug-Resistant Escherichia coli in
Drinking-Water in and around Ayodhya (U.P.) , India. *Indian J Vet Sci Biotechnol* 2023; **19**:
112–5.

46. Bialvaei AZ, Kafil HS. Colistin, mechanisms and prevalence of resistance. *Curr Med Res*
Opin 2015. Available at:
https://www.tandfonline.com/doi/abs/10.1185/03007995.2015.1018989. Accessed September
2, 2023.

47. Kumar M, Saha S, Subudhi E. More Furious Than Ever: *Escherichia coli* -Acquired Co-
resistance Toward Colistin and Carbapenems. *Clin Infect Dis* 2016: ciw508.

48. Marathe NP, Pal C, Gaikwad SS, Jonsson V, Kristiansson E, Larsson DGJ. Untreated
urban waste contaminates Indian river sediments with resistance genes to last resort
antibiotics. *Water Res* 2017; **124**: 388–97.

49. Mitra S, Basu S, Rath S, Sahu SK. Colistin resistance in Gram-negative ocular infections:
prevalence, clinical outcome and antibiotic susceptibility patterns. *Int Ophthalmol* 2020; **40**:
1307–17.

50. Ragupathi NKD, Sethuvel DPM, Anandan S, *et al.* First hybrid complete genome of
Aeromonas veronii reveals chromosome-mediated novel structural variant mcr-3.30 from a
human clinical sample. *Access Microbiol* 2020; **2**. Available at:
https://www.microbiologyresearch.org/content/journal/acmi/10.1099/acmi.0.000103.
Accessed August 17, 2023.

51. Li Z, Cao Y, Yi L, Liu J-H, Yang Q. Emergent Polymyxin Resistance: End of an Era?
Open Forum Infect Dis 2019; **6**: ofz368.

52. Sreejith S, Manjusha P, Prathuish P, *et al.* Predicting human risk with multidrug resistant
Enterobacter hormaechei MS2 with MCR 9 gene isolated from the feces of healthy broiler
through whole genome sequence based analysis. 2023. Available at:
https://www.researchsquare.com. Accessed September 28, 2023.

53. Carattoli A, Villa L, Feudi C, *et al.* Novel plasmid-mediated colistin resistance mcr-4
gene in Salmonella and Escherichia coli, Italy 2013, Spain and Belgium, 2015 to 2016.
Eurosurveillance 2017; **22**. Available at:
https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2017.22.31.30589.
Accessed August 24, 2023.

54. Zurfluh K, Treier A, Schmitt K, Stephan R. Mobile fosfomycin resistance genes in
Enterobacteriaceae—An increasing threat. *MicrobiologyOpen* 2020; **9**. Available at:
https://onlinelibrary.wiley.com/doi/10.1002/mbo3.1135. Accessed September 2, 2023.

55. Singh S, Pathak A, Kumar A, *et al.* Emergence of Chromosome-Borne Colistin
Resistance Gene *mcr-1* in Clinical Isolates of Klebsiella pneumoniae from India. *Antimicrob*
Agents Chemother 2018; **62**: e01885-17.

56. RAHMAN M, Ahmad S. 549. First Report for Emergence of Chromosomal Borne Colistin Resistance Gene mcr-1 in a Clinical Acinetobacter Baumannii Isolates from India. *Open Forum Infect Dis* 2019; **6**: S261–2.

57. Pathak A, Singh S, Kumar A, Prasad KN. Emergence of chromosome borne colistin resistance gene, mcr-1 in clinical isolates of Pseudomonas aeruginosa. *Int J Infect Dis* 2020; **101**: 22.

58. Seethalakshmi PS, Prabhakaran A, Kiran GS, Selvin J. First Report on the Circulation of *mcr-9* Bearing *Enterobacteriaceae* Isolated in a Rural Environmental Water Body of India. *SSRN Electron J* 2022. Available at: https://www.ssrn.com/abstract=4280949. Accessed August 17, 2023.

59. Elizabeth R, Baishya S, Kalita B, *et al.* Colistin exposure enhances expression of eptB in colistin-resistant Escherichia coli co-harboring mcr-1. *Sci Rep* 2022; **12**: 1348.

60. Bir R, Gautam H, Arif N, *et al.* Analysis of colistin resistance in carbapenem-resistant *Enterobacterales* and XDR *Klebsiella pneumoniae*. *Ther Adv Infect Dis* 2022; **9**: 204993612210806.

61. Reddy BRC, Geetha RV, Singh M, Rani RU, Nekkanti KN. Mcr-1 expression in progression of colistin resistance gram negative bacilli of clinical specimens derived from Intensive Care Units, wards and hospital setting of Deccan Eco Region of Southern India. *J Pharm Negat Results* 2022; **13**.

62. Singh S, Pathak A, Rahman M, *et al.* Genetic Characterisation of Colistin Resistant Klebsiella pneumoniae Clinical Isolates From North India. *Front Cell Infect Microbiol* 2021; **11**: 666030.

63. Elizabeth R, Wangkheimayum J, Singha KM, Chanda DD, Bhattacharjee A. Subinhibitory concentration stress of colistin enhanced PhoPQ expression in *Escherichia coli* harboring *mcr* 1. *J Basic Microbiol* 2021; **61**: 1029–34.

64. Pathak A, Singh S, Prasad N, Prasad KN. Sat-423 emergence of blandm and mcr-1 positive pan- and extremely- drug resistant bacterial infections in patients with renal diseases. *Kidney Int Rep* 2020; **5**: S176–7.

65. Roy S, Das P, Das S, *et al.* Detection of the emergence of *mcr-1* –mediated colistin-resistant *Escherichia coli* and *Klebsiella pneumoniae* through a hospital-based surveillance in an oncology center in eastern India. *Infect Control Hosp Epidemiol* 2020; **41**: 378–80.

66. Subramaniam N, Muthukrishnan A. Oral mucositis and microbial colonization in oral cancer patients undergoing radiotherapy and chemotherapy: A prospective analysis in a tertiary care dental hospital. *J Investig Clin Dent* 2019; **10**. Available at: https://onlinelibrary.wiley.com/doi/10.1111/jicd.12454. Accessed August 17, 2023.

67. Bernasconi OJ, Kuenzli E, Pires J, *et al.* Travelers Can Import Colistin-Resistant Enterobacteriaceae, Including Those Possessing the Plasmid-Mediated *mcr-1* Gene. *Antimicrob Agents Chemother* 2016; **60**: 5080–4.